EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

L-carnitine and Ginkgo biloba Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism

Amany E Nofal iD, Hind S AboShabaan iD, Walaa A Fadda iD, Rafik E Ereba iD, Sherin M Elsharkawy, Heba M Hathout iD

Cells · 2024

DOI: 10.3390/cells13090732 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Amany E Nofal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Zoology Department, Faculty of Science, Menoufia University, Shebin El-Kom 32511, Egypt. Hauptthemen laut MEDLINE: Ginkgo biloba, Liver, Carnitine, Dietary Supplements. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment strategies for steatohepatitis are of special interest given the high prevalence of obesity and fatty liver disease worldwide. This study aimed to investigate the potential therapeutic mechanism of L-carnitine (LC) and Ginkgo biloba leaf extract (GB) supplementation in ameliorating the adverse effects of hyperlipidemia and hepatosteatosis induced by a high-cholesterol diet (HCD) in an animal model. The study involved 50 rats divided into five groups, including a control group, a group receiving only an HCD, and three groups receiving an HCD along with either LC (300 mg LC/kg bw), GB (100 mg GB/kg bw), or both. After eight weeks, various parameters related to lipid and glucose metabolism, antioxidant capacity, histopathology, immune reactivity, and liver ultrastructure were measured. LC + GB supplementation reduced serum total cholesterol, triglyceride, low-density lipoprotein cholesterol, glucose, insulin, HOMA-IR, alanine transaminase, and aspartate transaminase levels and increased high-density lipoprotein cholesterol levels compared with those in the HCD group. Additionally, treatment with both supplements improved antioxidant ability and reduced lipid peroxidation. The histological examination confirmed that the combination therapy reduced liver steatosis and fibrosis while also improving the appearance of cell organelles in the ultrastructural hepatocytes. Finally, the immunohistochemical analysis indicated that cotreatment with LC + GB upregulated the immune expression of GLP-1 and β-Cat in liver sections that were similar to those of the control animals. Mono-treatment with LC or GB alone substantially but not completely protected the liver tissue, while the combined use of LC and GB may be more effective in treating liver damage caused by high cholesterol than either supplement alone by regulating hepatic oxidative stress and the protein expression of GLP-1 and β-Cat.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ginkgo bilobaLiverCarnitineDietary SupplementsPlant ExtractsDyslipidemiasAnimalsMaleRatsFatty LiverRats, Sprague-DawleyLipid MetabolismAntioxidantsDiet, High-FatGinkgo Extract

Stichwörter der Autor:innen

GLP-1Rhyperlipidemiainsulin resistancemetabolismnatural supplementsβ-catenin

Substanzen

CarnitinePlant ExtractsGinkgo biloba extractAntioxidantsGinkgo Extract

Autor:innen und Institutionen

  • Zoology Department, Faculty of Science, Menoufia University, Shebin El-Kom 32511, Egypt.
  • Clinical Pathology Department, National Liver Institute Hospital, Menoufia University, Shebin El-Kom 32511, Egypt.
  • Human Anatomy and Embryology Department, Faculty of Medicine, Menoufia University, Shebin El-Kom 32511, Egypt.
  • Department of Pharmacology, Faculty of Medicine, Al-Azhar University, Cario 11511, Egypt.
  • Physiology Department, Medicine College, Banha University, Banha 13511, Egypt.
  • Natural Resources Department, Faculty of African Postgraduate Studies, Cairo University, Giza 12613, Egypt.

ORCID-Profile: Amany E Nofal, Hind S AboShabaan, Walaa A Fadda, Rafik E Ereba, Heba M Hathout

Zitieren

APA

Nofal, A. E., AboShabaan, H. S., Fadda, W. A., Ereba, R. E., Elsharkawy, S. M., & Hathout, H. M. (2024). L-carnitine and Ginkgo biloba Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism. Cells. https://doi.org/10.3390/cells13090732

Vancouver

Nofal AE, AboShabaan HS, Fadda WA, Ereba RE, Elsharkawy SM, Hathout HM. L-carnitine and Ginkgo biloba Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism. Cells. 2024. doi:10.3390/cells13090732

BibTeX
@article{Nofal2024,
  author = {Nofal, Amany E and AboShabaan, Hind S and Fadda, Walaa A and Ereba, Rafik E and Elsharkawy, Sherin M and Hathout, Heba M},
  title = {L-carnitine and Ginkgo biloba Supplementation In Vivo Ameliorates HCD-Induced Steatohepatitis and Dyslipidemia by Regulating Hepatic Metabolism},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13090732}
}
Kostenlos starten →